FDA grants Dr. Reddy's first tentative approval for a generic $40 lenacapavir HIV prevention shot

For four decades the global response to HIV has followed a familiar and discouraging sequence: the medicines that work best arrive first in wealthy countries and only much later, sometimes a decade later, in the countries where most new infections occur. Lenacapavir, a long-acting antiretroviral given as two injections a year, appeared likely to repeat that pattern. Gilead Sciences won US approval for the prevention version, sold as Yeztugo, in June 2025, at a US list price of $28,218 a year, a figure that put it beyond the reach of most health systems in Africa, Asia and Latin America.

On November 2, 2026, that sequence was interrupted. Dr. Reddy's Laboratories said the US Food and Drug Administration had granted tentative approval to its generic injectable lenacapavir for pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg, or 77 pounds. The decision does not allow the company to sell the product in the United States, where Gilead's patent and exclusivity protections still apply. It does something with wider consequences: it gives global procurement agencies and national regulators a stringent regulatory reference for a product priced at $40 per person per year.

The approval is the first among six manufacturers that have taken licences from Gilead, and it came 16 months after the originator product was cleared for prevention. Generic versions of HIV medicines have historically reached low-income countries years after their branded equivalents. Unitaid, the Clinton Health Access Initiative and the Wits Reproductive Health and HIV Institute, part of South Africa's University of the Witwatersrand, worked with Dr. Reddy's to compress that interval, providing financial and technical support before any regulator had signed off on the product.

The need is large and stubbornly stable. The World Health Organization estimates that 41 million people were living with HIV worldwide and that 570,000 died from HIV-related causes last year. The epidemic, now 44 years old, still infects 1.3 million people a year and has killed 44 million since it emerged, according to WHO estimates cited in coverage of the approval. Prevention is where the epidemic's trajectory is decided, and a twice-yearly injection removes the daily adherence problem that has limited oral PrEP since it became available.

Key Facts

Reuters reported on November 2 that Dr. Reddy's was the first of six Gilead licensees to obtain tentative FDA approval for generic lenacapavir, a status reserved for drugs that meet all of the agency's safety, efficacy and quality standards but cannot yet be sold in the United States because of patent or exclusivity barriers. The approval covers pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1, and it was announced on a Monday morning by the manufacturer and the organisations that helped speed development.

Pharmabiz reported on November 3 that the approval was granted under the FDA's PEPFAR programme, the longstanding mechanism used to assure the quality of HIV medicines that the US government provides to other countries, and that the label covers adults and adolescents weighing at least 35 kg. The trade publication also noted that Dr. Reddy's intends to pursue WHO prequalification, which together with national registrations is normally required before countries can buy at volume.

The price is the headline number. The Associated Press reported on November 2 that the generic will cost $40 a year per person in the countries where it will be sold, the same price as daily preventive pills, against a US list price of $28,218 a year for branded Yeztugo. That commitment covers the 120 low- and middle-income countries in Gilead's voluntary licence, and it rests on a September 2025 agreement between Dr. Reddy's, Unitaid, Wits RHI and CHAI. Gilead granted the licence itself in October 2024.

Demand already exists. More than 125,000 people in 10 early adopter African countries have started Gilead's lenacapavir even before generic supply becomes available, according to the joint announcement issued in Geneva by CHAI and Unitaid. In two late-stage studies of people at high risk, the injections nearly eliminated new infections. Unitaid said Zambia could be among the first countries to receive generic supplies, with initial doses expected to reach a few low-income countries by the end of 2026 and broader rollout across eligible countries in 2027.

The regulatory mechanics matter as much as the science. Jessica Burry, a technical officer at Unitaid, told Reuters on November 2 that some countries would be able to fast-track their own approvals through a reliance mechanism on the FDA, and that the decision could also help accelerate procurement. Because tentative approval is granted only after a full review of manufacturing quality, the letter from Washington functions as an audited seal that smaller regulators can accept without duplicating work they are not equipped to do.

Analysis

The headline comparison, $40 against $28,218, describes two different markets rather than a straightforward discount. Gilead's US price reflects a patent-protected product sold through insurers and federal programmes; the $40 figure reflects a voluntary licence negotiated for countries where ministries and households pay directly. What the approval changes is the supply side. Until now, the 120 countries had a promise, a licence and a price, but no approved generic product that procurers could buy with confidence.

The bigger picture here is that the bottleneck in global health has moved from invention to industrial and regulatory execution. Lenacapavir works: two injections a year, near-complete protection in trials, no daily pill to remember. Reaching the 20 million people that CHAI's Carolyn Amole says need PrEP requires a manufacturer with capacity, a stringent regulatory approval, WHO prequalification and national registrations, roughly in that order. The FDA tentative approval clears one step and gives the others something to lean on.

The 16-month interval deserves scrutiny as a model rather than a curiosity. Philippe Duneton, executive director of Unitaid, said the agency's early risk-taking shortened the gap between a scientific breakthrough and real access, and that with best-in-class HIV treatment the partnership delivered in four years what used to take ten. With lenacapavir, he said, that timeline has been cut to just over a year. If the compression holds for other products, licensing plus donor-backed development plus regulatory reliance becomes a repeatable playbook. If it does not, lenacapavir remains an exception that proves how unusual the alignment was.

A caution is warranted. Tentative approval is not a launch. Procurement contracts, country registrations, cold chain arrangements and clinician training all sit between the FDA letter and a clinic in Zambia. The US market also stays closed to the generic, which limits the revenue Dr. Reddy's can earn from the product and therefore its incentive to keep adding capacity beyond the volumes that donors underwrite. The $40 guarantee is a negotiated commitment, not a market outcome, and it holds only as long as the licence and the partnership behind it hold.

Why It Matters

For the 1.3 million people infected each year, a twice-yearly injection that nearly eliminated infections in trials is a different kind of prevention tool rather than a marginal improvement. Daily oral PrEP works only when it is taken, and adherence has always been the weak point in programmes aimed at people who do not see themselves as patients. Carmen Perez Casas, HIV lead at Unitaid, made the point directly: people do not always take their daily dose, and if you do not take it, you cannot be protected.

For the 120 countries, the approval provides a defensible basis for purchase decisions without waiting for a full local review, which can shift budgets within a single fiscal cycle instead of across several. The Associated Press reported on November 2 that advocates believe an affordable, high-quality generic could help scale PrEP to the 20 million people worldwide who need it. That is a statement about ambition, not a forecast, but it is now a procurement question rather than a scientific one.

For the industry, the approval tests whether voluntary licensing can deliver at speed. Six licensees exist and one has a tentative approval, which gives the others both a template and a competitor.

Next Up

Attention turns to WHO prequalification and national filings, then to procurement and delivery. Initial supplies are expected to reach a few low-income countries by the end of 2026, with broader rollout in 2027. Zambia is the name Unitaid has put forward as a possible first recipient, and how quickly doses arrive there will be the first real test of the timeline that partners have promised.

The other variable is money and demand: whether donors fund scale-up to the 20 million people who need PrEP, and whether the remaining licensees follow Dr. Reddy's through the same pathway. Deepak Sapra, chief executive of API and services at Dr. Reddy's, framed the approval as validation of the company's scientific and manufacturing capability and as a step toward making the twice-yearly option available across low- and middle-income countries. The next twelve months will show whether that framing survives contact with procurement.